- Home
- CSTL vs CHI Comparison
CSTL vs CHI Comparison
Compare CSTL & CHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CSTL | CHI |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 806.3M | 930.8M |
| IPO Year | 2019 | 2002 |
Fundamental Metrics
Financial Performance| Metric | CSTL | CHI |
|---|---|---|
| Price | $24.32 | $11.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $47.17 | N/A |
| AVG Volume (30 Days) | ★ 261.5K | 214.7K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.90% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $344,229,000.00 | N/A |
| Revenue This Year | $2.42 | N/A |
| Revenue Next Year | $12.69 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.66 | N/A |
| 52 Week Low | $14.59 | $9.35 |
| 52 Week High | $44.28 | $12.13 |
Technical Indicators
Market Signals| Indicator | CSTL | CHI |
|---|---|---|
| Relative Strength Index (RSI) | 42.53 | 62.83 |
| Support Level | $21.77 | $10.31 |
| Resistance Level | $26.19 | N/A |
| Average True Range (ATR) | 1.16 | 0.30 |
| MACD | 0.22 | 0.10 |
| Stochastic Oscillator | 56.85 | 78.99 |
Price Performance
Historical ComparisonAbout CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.